Document is current
Any future updates will be listed below
-
Authors
Corpechot, Christophe https://orcid.org/0000-0002-7920-9784
Londoño, Maria-Carlota
Villamil, Alejandra
Ytting, Henriette
Tanaka, Atsushi https://orcid.org/0000-0002-6358-5283
Beuers, Ulrich https://orcid.org/0000-0001-5114-7799
- License Information
-
More Information
Article History
First Online: 10 October 2025
Competing interests
: C.C. reports grants from Intercept Pharmaceuticals and Arrow Génériques, and consulting work for Cymabay, Gilead, Ipsen, Calliditas, GSK, Mirum, Advanz, Echosens and Intercept Pharmaceuticals; M.-C.L. reports grants from Gilead and Mirum; consulting work for Advanz, Mirum, Gilead, Ipsen, Falk and GSK; and lectures for Advanz, GSK, Gilead and Ipsen. H.Y. reports advisory board participation for IPSEN and congress participation by invitation from IPSEN. A.V. reports speaker fees from Intercept. A.T. reports consultant work for GSK, Kowa, Kaken Pharmaceuticals, Ipsen, Mirum, AbbVie and Gilead. U.B. reports consulting and/or lecture fees from Abacus, Amgen, Behring, GSK, Ipsen, Mirum and Ono.
